SCHEMBL6569470

SCHEMBL6569470

CCCCSC(=S)N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
POLB P06746 1/20 0.46
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
ALDH1A1 P00352 8/20 0.42
MGLL Q99685 6/20 0.42
LMNA P02545 5/20 0.42
HTT P42858 4/20 0.42
ALDH2 P05091 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TP53 P04637 2/20 0.42
HSP90AA1 P07900 2/20 0.42
CYP3A4 P08684 2/20 0.42
FBP1 P09467 2/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27722887 0.91 POLB (0.41) CYP1A2CYP2C9CYP2C19POLBNOS3
SCHEMBL11850440 0.91 MGLL (0.42) CYP1A2CYP2C9CYP2C19POLBNOS3
SCHEMBL11169576 0.91 MGLL (0.42) CYP1A2CYP2C9CYP2C19POLBNOS3
SCHEMBL11043122 0.85
SCHEMBL29857470 0.83 MGLL (0.43) CYP1A2CYP2C9CYP2C19POLBNOS3
Guanidine SCHEMBL9056184 0.82 NOS3 (0.47) CYP1A2CYP2C9CYP2C19POLBNOS3
SCHEMBL8986674 0.82 NOS3 (0.45) CYP1A2CYP2C9CYP2C19POLBNOS3
SCHEMBL2362925 0.81 ALDH1A1 (0.42) CYP1A2CYP2C9CYP2C19POLBALDH1A1
SCHEMBL30446032 0.79 ALDH1A1 (0.50) CYP1A2CYP2C9CYP2C19ALDH1A1MGLL
SCHEMBL11143218 0.79 CYP1A2 (0.43) CYP1A2CYP2C9CYP2C19POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12539650-B2 Method for making embedded hydrogel contact lenses ALCON INC. (CH) 2026-02-03 US claimed
EP-4514595-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2025-03-05 EP claimed
EP-4240578-B1 METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES ALCON INC (CH) 2024-12-18 EP claimed
US-11886045-B2 Method for making photochromic contact lenses ALCON INC. (CH) 2024-01-30 US claimed
WO-2023209570-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES ALCON INC. (CH) 2023-11-02 WO claimed
US-20230339149-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES ALCON INC. (CH) 2023-10-26 US claimed
EP-4240578-A1 METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES Alcon Inc. (CH) 2023-09-13 EP claimed
WO-2022097048-A1 METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES ALCON INC. (CH) 2022-05-12 WO claimed
US-20220137433-A1 METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES ALCON INC. (CH) 2022-05-05 US claimed
US-6265499-B1 POLYMERIZING MIXTURE MENICON CO., LTD. (JP) 2001-07-24 US claimed
US-20260131506-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES ALCON INC (CH) 2026-05-14 US disclosed
US-12539650-B2 Method for making embedded hydrogel contact lenses ALCON INC. (CH) 2026-02-03 US disclosed
EP-4514595-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2025-03-05 EP disclosed
EP-4240578-B1 METHOD FOR MAKING PHOTOCHROMIC CONTACT LENSES ALCON INC (CH) 2024-12-18 EP disclosed
US-11886045-B2 Method for making photochromic contact lenses ALCON INC. (CH) 2024-01-30 US disclosed
US-6265499-B1 POLYMERIZING MIXTURE MENICON CO., LTD. (JP) 2001-07-24 US disclosed
EP-0921134-A1 Process for producing a shaped product Menicon Co., Ltd. (JP) 1999-06-09 EP disclosed
US-5866047-A Process for producing a shaped product MENICON CO., LTD. (JP) 1999-02-02 US disclosed
EP-0814095-A2 Process for producing a shaped product Menicon Co., Ltd. (JP) 1997-12-29 EP disclosed
EP-0421388-A2 Positive-acting photoresist composition MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539650-B2 Method for making embedded hydrogel contact lenses INF2, CRYZ, CRYAA CYP1A2 849/4885CYP2C9 1867/4885CYP2C19 2132/4885
US-20260131506-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES CRYZ, CRYAB, CRYAA CYP1A2 1256/4885CYP2C9 799/4885CYP2C19 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.